FACTORS AFFECTING COVID-19 OUTCOMES IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
DOI:
https://doi.org/10.15407/exp-oncology.2024.03.260Keywords:
COVID-19 mortality, COVID-19 risk factors, hematological malignanciesAbstract
Background. Patients with hematological malignancies (HM) are considered to have a high risk of developing severe and life-threatening infections including COVID-19 because of immune deficiency and immunosuppressive treatments. Although the COVID pandemic spread worldwide, morbidity and mortality data varied from country to country. A more accurate identification of risk factors would allow the improvement of the clinical management of HM patients. Aim. This study aimed to determine real-life data — the mortality rate, clinical outcomes, and risk factors affecting mortality in patients with HM and COVID-19 at the Riga East University Hospital (REUH) in Latvia. Materials and Methods. In this retrospective non-interventional cohort study, we included adult patients treated in REUH with ongoing HM and laboratory- confirmed COVID-19 observed between December 1st, 2020, and March 31st, 2023. All data were analyzed using descriptive statistics, binary logistic regression, univariable Cox regression model, and other methods. Results. We registered 156 patients with 11 different HMs. Multiple myeloma, non-Hodgkin lymphoma, and acute myeloid leukemia were the most common HM. COVID-19 mortality rate was 19.9% (31/156). Factors increasing the risk of death included the severity of COVID-19 (p < 0.001), the accession of bacterial infection (p < 0.001), longer hospital stay (p = 0.037), absolute neutrophil count (ANC) ≤ 0.5 × 109/mm3 (p = 0.014), fever (p = 0.039), and acute myeloid leukemia (p = 0.002). We also confirmed that the mortality in the third pandemic wave was significantly lower than in the second wave (p = 0.002). Although vaccination seemed to be a risk-mitigating factor (58.8% [10/17] of those who died from COVID-19 were not vaccinated), no statistically important correlation was found (p = 0.690). Conclusion. This survey confirmed that the COVID-19 mortality rate was higher in patients with HM (19.9% [31/156]) than in the population. ANC, severity of COVID-19, accession of bacterial infection, hospital stay, fever, and acute myeloid leukemia were the factors that increased mortality in HM patients.
References
Cucinotta D, Vanelli M. WHO declares COVID19 a pandemic. Acta Biomed. 2020;91(1):157160. https://doi. org/10.23750/abm.v91i1.9397
COVID19 excess mortality collaborators. Estimating excess mortality due to the COVID19 pandemic: a syste matic analysis of COVID19related mortality, 202021. Lancet. 2022;399(10334):15131536. https://doi.org/10.1016/ S01406736(21)027963
Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID19: a systematic review and metaanalysis of 3377 patients. Blood. 2020;136(25):28812892. https://doi.org/10.1182/blood.2020008824
Henley SJ, Dowling NF, Ahmad FB, et al. COVID19 and other underlying causes of cancer deaths — United States, January 2018–July 2022. MMWR. 2022;71:15831588. http://dx.doi.org/10.15585/mmwr.mm7150a3
HosseiniMoghaddam SM, Shepherd FA, Swayze S, et al. SARSCoV2 infection, hospitalization, and mor tality in adults with and without cancer. JAMA Netw Open. 2023;6(8):e2331617. https://doi.org/10.1001/jamanet workopen.2023.31617
Marchesi F, SalmantonGarcía J, Emarah Z, et al. COVID19 in adult acute myeloid leukemia patients: a longterm fol lowup study from the European Hematology Association survey (EPICOVIDEHA). Haematologica. 2023;108(1):22 33. https://doi.org/10.3324/haematol.2022.280847
Pagano L, SalmantonGarcía J, Marchesi F, et al. COVID19 infection in adult patients with hematological malignan cies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168. https://doi. org/10.1186/s13045021011770
ISSN 1812-9269. Experimental Oncology 46 (3). 2024
Latvijas Republikas valsts kontrole. 2022. Lēmumu pieņemšana un krīzes pārvaldība Covid19 pandēmijas laikā. https://lrvk.gov.lv/lv/getrevisionfile/29552V1Ejaf2ueRQbdU_dZw4V_iLd5x_8Wa.pdf. Accessed March 28, 2024.
McIntosh K, Rajesh MD, Gandhi T et al. COVID19: Clinical features. UpToDate. 2024. https://wwwuptodatecom. db.rsu.lv/contents/covid19clinicalfeatures?search=covid%2019%20severity&source=search_result&selectedTitle
=1%7E150&usage_type=default&display_rank=1 [Accessed March 25, 2024].
Johns Hopkins University & Medicine. Coronavirus Resource Center. Available at: https://coronavirus.jhu.edu/data/ mortality. [Accessed March 25, 2024].
Terpos E, Trougakos IP, Gavriatopoulou M, et al. Low neutralizing antibody responses against SARSCoV2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood. 2021;137(26):36743676. https://doi. org/10.1182/blood.2021011904
Fan Y, Li X, Zhang L, et al. SARSCoV2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. 2022;7(1):141. https://doi.org/10.1038/s4139202200997x
Blair HA. Remdesivir: a review in COVID19. Drugs. 2023;83(13):12151237. https://doi.org/10.1007/s40265023019260
Tian L, Pang Z, Li M, et al. Molnupiravir and its antiviral activity against COVID19. Front Immunol. 2022;13:855496 https://doi.org/10.3389/fimmu.2022.855496.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Experimental Oncology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.